Larimar Therapeutics (LRMR) Reports $31.1M Q3 Net Loss; Cash Runway Into Late Q2 2027
Larimar reported a Q3 2026 net loss of $31.1M, or $0.29 per share, versus $47.7M, or $0.61, in Q3 2025. It had $128.7M in cash, cash equivalents and marketable securities at September 30, 2026, and projects runway into late Q2 2027.Material DetailsContext by AI AnalystThis is a clinical-stage compa…